Advances in Therapy

, Volume 29, Issue 6, pp 473–490 | Cite as

Besifloxacin Ophthalmic Suspension, 0.6%: a Novel Topical Fluoroquinolone for Bacterial Conjunctivitis

Review

Abstract

Acute bacterial conjunctivitis, the most common cause of conjunctivitis, is responsible for approximately 1% of all primary-care consultations. Of the topical ophthalmic antibiotics used to treat acute bacterial conjunctivitis, fluoroquinolones are especially useful because they possess a broad antibacterial spectrum, are bactericidal in action, are generally well tolerated, and have been less prone to development of bacterial resistance. Besifloxacin, the latest advanced fluoroquinolone approved for treating bacterial conjunctivitis, is the first fluoroquinolone developed specifically for topical ophthalmic use. It has a C-8 chlorine substituent and is known as a chloro-fluoroquinolone. Besifloxacin possesses relatively balanced dual-targeting activity against bacterial topoisomerase IV and DNA gyrase (topoisomerse II), two essential enzymes involved in bacterial DNA replication, leading to increased potency and decreased likelihood of bacterial resistance developing to besifloxacin. Microbiological data suggest a relatively high potency and rapid bactericidal activity for besifloxacin against common ocular pathogens, including bacteria resistant to other fluoroquinolones, especially resistant staphylococcal species. Randomized, double-masked, controlled clinical studies demonstrated the clinical efficacy of besifloxacin ophthalmic suspension 0.6% administered three-times daily for 5 days to be superior to the vehicle alone and similar to moxifloxacin ophthalmic solution 0.5% for bacterial conjunctivitis. In addition, besifloxacin ophthalmic suspension 0.6% administered two-times daily for 3 days was clinically more effective than the vehicle alone for bacterial conjunctivitis. Besifloxacin has also been shown in preclinical animal studies to be potentially effective for the “off-label” treatment of infections following ocular surgery, prophylaxis of endophthalmitis, and the treatment of bacterial keratitis. Taken together, clinical and preclinical animal studies indicate that besifloxacin is an important new option for the treatment of ocular infections.

Keywords

Acute bacterial conjunctivitis Bacterial resistance Besifloxacin Endophthalmitis Fluoroquinolones Keratitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McDonnell PJ. How do general practitioners manage eye disease in the community? Br J Ophthalmol. 1988;72:733–736.PubMedCrossRefGoogle Scholar
  2. 2.
    Diamant JI, Hwang DG. Therapy for bacterial conjunctivitis. Ophthalmol Clin North Am. 1999;12:15–20.CrossRefGoogle Scholar
  3. 3.
    Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother. 2007;8:1903–1921.PubMedCrossRefGoogle Scholar
  4. 4.
    Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis (Review). Cochrane Database Syst Rev. 2006;2:CD001211.Google Scholar
  5. 5.
    Høding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008;86:5–17.Google Scholar
  6. 6.
    Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician. 1998;57:735–746.PubMedGoogle Scholar
  7. 7.
    Drug Facts and Comparisons 2008. St. Louis, MO: Wolters Kluwer Health; 2008:1764–1765.Google Scholar
  8. 8.
    Besivance (package insert). Rochester, NY: Bausch & Lomb Inc.; April 2009.Google Scholar
  9. 9.
    Zymaxid (package insert). Irvine, CA: Allergan, Inc.; May 2010.Google Scholar
  10. 10.
    Kaliamurthy J, Nelson Jesudasan CA, Geraldine P, Parmar P, Kalawathy CM, Thomas PA. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res. 2005;37:117–122.PubMedCrossRefGoogle Scholar
  11. 11.
    Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49:S79–S83.PubMedCrossRefGoogle Scholar
  12. 12.
    Cambau E, Matrat S, Xiao-Su P, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009;63:443–450.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen FJ, Lo HJ. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect. 2003;36:1–9.PubMedGoogle Scholar
  14. 14.
    O’Brien TP. Evidence-based review of moxifloxacin. Int Ophthalmol Clin. 2006;46:61–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Schlech BA, Blondeau J. Future of ophthalmic antiinfective therapy and the role of moxifloxacin ophthalmic solution 0.5% (Vigamox®). Surv Ophthalmol. 2005;50:S64–S67.PubMedCrossRefGoogle Scholar
  16. 16.
    McDonald MD, Blondeau JM. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. J Cataract Refract Surg. 2010; 36:1588–1598PubMedCrossRefGoogle Scholar
  17. 17.
    Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008;145:951–958.PubMedCrossRefGoogle Scholar
  18. 18.
    Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg. 2008;34:814–818.PubMedCrossRefGoogle Scholar
  19. 19.
    Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivitis in South Florida. Ophthalmology. 2008;115:51–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms — results from the ARMOR 2009 surveillance study. Am J Ophthalmol. 2011;152:567–574.PubMedCrossRefGoogle Scholar
  21. 21.
    Chalita MR, Hofling-Lima AL, Paranhos A, Schor P, Belfort R. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol. 2004;137:43–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Adebayo A, Parikh JG, McCormick SA, et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctivitis isolates in the last decade at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. 2011;249:111–119.PubMedCrossRefGoogle Scholar
  23. 23.
    Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 2006;124:479–483.PubMedCrossRefGoogle Scholar
  24. 24.
    Ward KH, Lepage J-F, Driot J-Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther. 2007;23:243–256.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang J-Z, Cavet ME, Ward KW. Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. Curr Eye Res. 2008;33:923–932.PubMedCrossRefGoogle Scholar
  26. 26.
    Protzko E, Bowman L, Abelson M, Shapiro A; for the AzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48:3425–3429.PubMedCrossRefGoogle Scholar
  27. 27.
    Blondeau JM, Borsos S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J Chemother. 2007;19:146–151.PubMedGoogle Scholar
  28. 28.
    Mah FS, Romanowski EG, Kowalski RP, Yates Ka, Gordon YJ. Benzalkonium chloride (BAK) significantly enhances the antibacterial efficacy of gatifloxacin in the Staphylococcus aureus NZW rabbit keratitis model. Invest Ophthalmol Vis Sci. 2006;47: E-Abstract 1905, ARVO Meeting. Available at: http://abstracts.iovs.org//cgi/content/abstract/47/5/1905?sid=6efc2603-26f1-4d5f-827b-27ba1c7d3199. Accessed May 17 2012.
  29. 29.
    Kowalski RP, Kowalski BR, Romanowski EG, Mah FS, Thompson PP, Gordon YJ. The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy. Am J Ophthalmol. 2006;142:730–735.PubMedCrossRefGoogle Scholar
  30. 30.
    Mah FS, Romanowski EG, Kowalski RP, Yates KA, Gordon YJ. Does topical 0.3% gatifloxacin need BAK (benzalkonium chloride) to treat gatifloxacinresistant, methicillin-resistant Staphylococcus epidermidis in the NZW rabbit keratitis model? Invest Ophthalmol Vis Sci. 2007;48: E-abstract 4743 (ARVO Abstract). Available at: http://abstracts.iovs.org//cgi/content/abstract/48/5/4743?sid=4f898b23-a3b5-4b0b-a24bf8fd898c8b5f. Accessed May 17 2102.
  31. 31.
    Haas W, Gearinger LS, Usner DW, et al. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin opthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369–1379.PubMedGoogle Scholar
  32. 32.
    Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53:3552–3560.PubMedCrossRefGoogle Scholar
  33. 33.
    Haas W, Pillar C, Hesje CK, Sanfilippo CM, Morris TW. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother. 2010;65:1441–1447.PubMedCrossRefGoogle Scholar
  34. 34.
    Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride. J Antimicrob Chemother. 2011;66:840–844.PubMedCrossRefGoogle Scholar
  35. 35.
    Sanfilippo CM, Hesje C, Haas W, Morris TW. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57:363–371.PubMedCrossRefGoogle Scholar
  36. 36.
    Shinabarger DL, Zurenko GE, Hesje CK, Sanfilippo CM, Morris TW, Haas W. Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroquinolone besifloxacin. J Chemother. 2011;23:80–86.PubMedGoogle Scholar
  37. 37.
    Proksch JW, Granvil CP, Siou-Mermet R, et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25:335–344.PubMedCrossRefGoogle Scholar
  38. 38.
    Torkildsen G, Proksch JW, Shapiro S, Lynch SK, Comstock TL. Concentrations of besifloxacin, gatifloxacin and moxifloxacin in human conjunctiva after topical ocular administration. Clin Ophthalmol. 2010;4:331–341.PubMedGoogle Scholar
  39. 39.
    Donnenfeld ED, Comstock TL, Proksch JW. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. J Cataract Refract Surg. 2011;37:1082–1089.PubMedCrossRefGoogle Scholar
  40. 40.
    Yoshida J, Kim A, Pratzer KA, Stark WJ. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. J Cataract Refract Surg. 2010;36:1499–1502.PubMedCrossRefGoogle Scholar
  41. 41.
    Segreti J, Jones RN, Bertino JS, Jr. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. J Ocul Pharmacol Ther. 2012;28:3–11.PubMedCrossRefGoogle Scholar
  42. 42.
    Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Pediatr Drugs. 2010;12:105–112.CrossRefGoogle Scholar
  43. 43.
    Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25:1159–1169.PubMedCrossRefGoogle Scholar
  44. 44.
    Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31:514–526.PubMedCrossRefGoogle Scholar
  45. 45.
    McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116:1615–1623.PubMedCrossRefGoogle Scholar
  46. 46.
    Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL. Efficacy and tolerability of besifloxacin 0.6% ophthalmic suspension administered twice daily for three days in the treatment of bacterial conjunctivitis: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Clin Ther. 2011;33:13–26.PubMedCrossRefGoogle Scholar
  47. 47.
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and dose compliance. Clin Ther. 2001;23:1296–1310.PubMedCrossRefGoogle Scholar
  48. 48.
    Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: A review of literature. J Behav Med. 2008;31:213–224.PubMedCrossRefGoogle Scholar
  49. 49.
    Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25:2307–2335.PubMedCrossRefGoogle Scholar
  50. 50.
    Comstock TL, Paterno MR, DeCory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Invest. 2010;30:675–685.CrossRefGoogle Scholar
  51. 51.
    Norcross EW, Sanders ME, Moore Q III, et al. Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis. J Ocul Pharmacol Ther. 2010;26:237–243.PubMedCrossRefGoogle Scholar
  52. 52.
    Sanders ME, Moore QC, Norcross EWM, et al. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of Pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. Cornea. 2011;30:83–90.PubMedCrossRefGoogle Scholar
  53. 53.
    Michaud L. Efficacy of besifloxacin in the treatment of corneal ulcer. Clin Refract Optom. 2011;22:90–93.Google Scholar
  54. 54.
    Sanders ME, Norcross EW, Moore QC 3rd, Shafiee A, Marquart ME. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. Cornea. 2009;28:1055–1060.PubMedCrossRefGoogle Scholar
  55. 55.
    Sanders ME, Moore QC 3rd, Norcross EW, Shafiee A, Marquart ME. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. J Ocul Pharmacol Ther. 2010;26:193–198.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2012

Authors and Affiliations

  1. 1.Ocular Microbiology Laboratory, Bascom Palmer Eye InstituteUniversity of Miami, Miller School of Medicine, Palm Beach GardensMiamiUSA

Personalised recommendations